Toll-like receptor 2 monoclonal antibody or/and Toll-like receptor 4 monoclonal antibody increase counts of Lactobacilli and Bifidobacteria in dextran sulfate sodium-induced colitis in mice

被引:30
作者
Dong, Le [1 ]
Li, Juan [2 ]
Liu, Yi [1 ]
Yue, Wenjie [1 ]
Luo, Xiaoting [1 ]
机构
[1] Fudan Univ, Huashan Hosp, Dept Gastroenterol, Shanghai 200040, Peoples R China
[2] Yijishan Hosp, Wannan Med Coll, Dept Gastroenterol, Wuhu, Anhui, Peoples R China
关键词
Bifidobacteria; dextran sulfate sodium-induced colitis; Lactobacilli; Toll-like receptor 2 monoclonal antibody; Toll-like receptor 4 monoclonal antibody; ulcerative colitis; INFLAMMATORY-BOWEL-DISEASE; NF-KAPPA-B; ULCERATIVE-COLITIS; MURINE COLITIS; PROBIOTICS; REMISSION; BACTERIA; PATTERNS;
D O I
10.1111/j.1440-1746.2011.06839.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aim: The accurate pathogenesis of ulcerative colitis (UC) is not yet well understood. Recently, Toll-like receptor 2 (TLR2), TLR4 and gut microbial flora have been proved as playing important roles in the process of UC. This study was to evaluate the effect of TLR2 and TLR4 monoclonal antibodies on gut microbial flora in dextran sulfate sodium (DSS)-induced colitis in a mouse model. Methods: We evaluated the effects of the TER2 and TER4 monoclonal antibodies on the development of DSS-induced colitis. Clinical symptoms were evaluated by the disease activity index (DAI), while tissue samples were evaluated by histological scoring (HS). Meanwhile, the mucosal mRNA expressions of TLR2, TLR4, interferon-gamma (IFN-gamma), interleukin-4 (IL-4) and IL-17 were analyzed by Realtime polymerase chain reaction (PCR). The mucosa' protein TRAF6, TAB 1, P-IKK, P-P38 alpha mitogen-activated protein kinase (MAPE) and Hun expressions of the TER2 and TER4 signaling pathways were analyzed using Western blot. The mucosal nuclear factor kappa B (ND-kappa B) was analyzed using electrophorelic mobility shift assay. Decal samples were obtained directly from the cecum for microbiological studies. Results: Expressions of TLR2 and TLR4 in colonic epithelial cells on DSS-nduced colitis were much higher than normal ones. After the treatment with TLR2mAb and TLR4mAb, DAI and HS were decreased significantly. The UC model group showed a conspicuous increase of Escherichia coli and decreases of Lactobacillus spp. and Bifidobacterium spp. After being treated with TER2mAb or/and TER4mAb. Lactobacillus spp. and Bifidobacterium spp. increased to the normal level. Conclusions: TLR2mAh and TLR4mAb can suppress the development of DSS-induced colitis and increase counts of Lactobacilli and Bifidobacteria.
引用
收藏
页码:110 / 119
页数:10
相关论文
共 22 条
[1]   Distinct Cytokine Patterns Identified from Multiplex Profiles of Murine DSS and TNBS-induced Colitis [J].
Alex, Philip ;
Zachos, Nicholas C. ;
Nguyen, Thuan ;
Gonzales, Liberty ;
Chen, Tian-E ;
Conklin, Laurie S. ;
Centola, Michoel ;
Li, Xuhang .
INFLAMMATORY BOWEL DISEASES, 2009, 15 (03) :341-352
[2]   The transcription factor NF-κB and human disease [J].
Baldwin, AS .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (01) :3-6
[3]   VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis [J].
Bibiloni, R ;
Fedorak, RN ;
Tannock, GW ;
Madsen, KL ;
Gionchetti, P ;
Campieri, M ;
De Simone, C ;
Sartor, RB .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (07) :1539-1546
[4]  
COOPER HS, 1993, LAB INVEST, V69, P238
[5]   Gut immune stimulation by non pathogenic Gram(+) and Gram(-) bacteria.: Comparison with a probiotic strain [J].
Dogi, C. A. ;
Galdeano, C. Maldonado ;
Perdigon, Gabriela .
CYTOKINE, 2008, 41 (03) :223-231
[6]   Microbial factors in inflammatory bowel disease [J].
Farrell, RJ ;
LaMont, JT .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2002, 31 (01) :41-+
[7]   Understanding why probiotic therapies can be effective in treating IBD [J].
Fedorak, Richard N. .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2008, 42 (08) :S111-S115
[8]   Probiotics in the treatment of human inflammatory bowel diseases - Update 2008 [J].
Fedorak, Richard Neil ;
Dieleman, Levinus Albert .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2008, 42 (06) :S97-S103
[9]  
FULLER R, 1989, J APPL BACTERIOL, V66, P365
[10]   Use of Probiotics in the treatment of inflammatory bowel disease [J].
Hart, AL ;
Stagg, AJ ;
Kamm, MA .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2003, 36 (02) :111-119